Physician profile
Lori Schaffer
NPI 1184167090
$10,524.52
in general payments reported to CMS, 2019-2025
58 companies · $2,661 in 2025
The $2,661 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,846 · 2022: $2,031 · 2023: $1,704 · 2024: $2,282 · 2025: $2,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,647.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,956.43 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,150.51 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,041.84 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $657.14 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $480.57 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $468.61 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $359.70 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $333.41 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $293.41 | 2021-2025 | Lifevest |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $292.65 | 2021-2025 | Xifaxan, Trulance |
| Amgen INC. | $265.94 | 2022-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $259.48 | 2021-2024 | Mounjaro, Trulicity, Amyvid |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $241.02 | 2025 | Caplyta |
| Alnylam Pharmaceuticals INC. | $209.69 | 2021-2025 | Amvuttra, Onpattro |
| Exact Sciences Corporation | $198.10 | 2023-2025 | Cologuard Collection Kit |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Schaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.